Diagnostic and Treatment Approach for Abnormal Cervical/Vaginal Findings with AUB
When abnormal cervical or vaginal examination findings are present alongside AUB, immediately perform age-appropriate endometrial sampling (≥35 years or <35 years with risk factors) while simultaneously investigating structural cervical/vaginal pathology, as the combination may indicate malignancy or premalignant conditions requiring urgent intervention. 1, 2
Immediate Diagnostic Algorithm
Age-Based Endometrial Assessment
Women ≥35 years with AUB require endometrial biopsy regardless of other findings 1:
- Endometrial aspiration is the preferred outpatient method, obtaining adequate samples in 86% of cases 3
- This avoids anesthesia risks and is less time-consuming than D&C 3
- If inadequate sample obtained (13.9% of cases, often due to atrophic endometrium), proceed to hysteroscopy and/or D&C 3
Women <35 years require endometrial biopsy if 1:
- Risk factors for endometrial cancer present (obesity, PCOS, diabetes, chronic anovulation)
- Excessive bleeding unresponsive to initial medical therapy
- Abnormal cervical/vaginal findings suggesting malignancy
Structural Evaluation
Transvaginal ultrasonography is the first-line imaging modality 1:
- Identifies polyps, fibroids (particularly submucosal), adenomyosis
- Saline infusion sonohysterography provides enhanced visualization when initial ultrasound is inconclusive 1
Cervical/Vaginal Pathology Assessment
When abnormal examination findings are present:
- Perform cervical cytology and HPV testing if not current 1
- Biopsy any visible cervical or vaginal lesions immediately
- Consider colposcopy for suspicious findings
Pattern Recognition for Bleeding Type
Anovulatory AUB (Irregular, Unpredictable Bleeding)
Screen for systemic causes 1, 4:
- TSH for thyroid dysfunction
- Prolactin if galactorrhea or amenorrhea present
- Hemoglobin A1c for diabetes
- Consider medication review (antipsychotics, antiepileptics, corticosteroids) 4
Critical pitfall: Chronic anovulation creates prolonged unopposed estrogen stimulation, increasing endometrial cancer risk—never delay endometrial sampling in appropriate candidates 1
Ovulatory AUB (Regular but Heavy Bleeding/Menorrhagia)
Coagulation screening is essential 1, 4:
- Von Willebrand disease is the most common coagulation defect causing menorrhagia 1
- Order CBC, PT/PTT, von Willebrand factor antigen and activity
- TSH to exclude thyroid dysfunction 1
Treatment Algorithm Based on Findings
When Endometrial Biopsy Shows:
Hyperplasia without atypia 1:
- Treat with cyclic or continuous progestin
- Oral progesterone 21 days per month is effective 1
Hyperplasia with atypia 1:
- Immediate referral to gynecologist
Adenocarcinoma 1:
- Immediate referral to gynecologic oncologist
When Structural Causes Identified
Clear structural pathology (polyps, fibroids) or medical management failure 1:
- Polypectomy for endometrial polyps
- Fibroidectomy for symptomatic fibroids
- Uterine artery embolization as alternative
- Endometrial ablation for completed childbearing
- Hysterectomy is most definitive treatment 1
Medical Management Options
First-line for anovulatory bleeding 1:
- Combination oral contraceptives
- Cyclic progestins to regulate cycles
First-line for ovulatory bleeding/menorrhagia 1:
- Levonorgestrel-releasing IUD is the most effective treatment 1
- NSAIDs reduce menstrual blood loss 1
- Tranexamic acid is FDA-approved but expensive 1
- Oral progesterone 21 days per month 1
Critical Management Considerations
The PALM-COEIN classification system should guide your systematic evaluation 5:
- PALM = structural causes (Polyp, Adenomyosis, Leiomyoma, Malignancy)
- COEIN = non-structural causes (Coagulopathy, Ovulatory dysfunction, Endometrial, Iatrogenic, Not classified)
Common pitfall: Approximately 50% of women with AUB develop mental health problems from anxiety and depression 4—address quality of life aggressively, as AUB significantly decreases life quality even when not life-threatening 4
Extragenital disorders are among the most frequent AUB causes 4—always consider endocrine, hematologic, and medication-related etiologies alongside gynecologic pathology 4